Clinical Trials · NCT05536804
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 134
- Start date
- Feb 2023
- Locations
- 27 sites, 6 countries
- Primary endpoint
- Percent Change from Baseline in Renal Sinus Fat Content (MRI)